Core Viewpoint - Rosen Law Firm is reminding investors who purchased Metagenomi, Inc. stock during its IPO of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Company Overview - Metagenomi, Inc. is described as a "genetic medicines company" that had a collaboration with Moderna, a leading Covid-19 vaccine company [4] - The company completed its IPO on February 13, 2024, selling 6.25 million shares at a price of $15 per share [4] Group 2: Legal Proceedings - A class action lawsuit has been filed against Metagenomi following the termination of its collaboration agreement with Moderna on May 1, 2024, which allegedly caused investor damages [4] - Investors who purchased Metagenomi stock during the IPO may be entitled to compensation through a contingency fee arrangement [1][2] Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3]
MGX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Metagenomi, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGX